Johnson & Johnson (JNJ.US) talquetamab is proposed for priority review in China to inhibit tumor formation and growth.

Zhito Finance APP has learned that on September 24, the CDE website showed that Johnson & Johnson's (JNJ.US) talquetamab (Chinese trade name: Tuolike) is proposed for priority review, for use in combination with pomalidomide for the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) who have previously received at least one prior line of therapy (including an anti-CD38 monoclonal antibody and lenalidomide).